Autovaccines for Chronic Urinary Tract Infections; Ten Years Follow-Up Experience
American Journal of Life Sciences
Volume 2, Issue 6-3, December 2014, Pages: 13-17
Received: Aug. 25, 2014; Accepted: Sep. 22, 2014; Published: Nov. 24, 2014
Views 3005      Downloads 126
Authors
Gallego-Vilar Daniel, FED, Department of Urology, Castellon Provincial Hospital, Castellon, Spain
Sanchis-Verdu Laura, Department of Urology, Castellon General Hospital, Castellon, Spain
Beltran Persiva Jose, FED, Department of Urology, Castellon Provincial Hospital, Castellon, Spain
Cuñat-Albert Enrique, Department of Urology, Castellon General Hospital, Castellon, Spain
Cervello-Grima Enrique, FED, Department of Urology, Castellon Provincial Hospital, Castellon, Spain
Gallego-Gomez Juan, Department of Urology, Castellon General Hospital, Castellon, Spain
Perez-Mestre Mateo, Department of Urology, Castellon Provincial Hospital, Castellon, Spain
Article Tools
Follow on us
Abstract
Introduction This study describes the impact of a daily sublingual Probelte Pharma autovaccine ® program to prevent recurrent symptomatic UTI in non-responders adults to conventional antibiotic prophylaxis. Material and Methods Observational prospective open study including patients with recurrent UTI. A sublingual vaccine containing ethanol-killed bacteria extract from specific patient´s uropathogenic strains were prepared from patient´s semen or urine sample . The main outcome criteria were the number and severity of symptomatic/clinical UTI, specific antibiotic dosage and duration of use, adverse effects if any, and necessity to stop or change the antibiotic was noted. Results Thirty-two patients met inclusion/exclusion criteria (17 men, 53.1%; 15 women, 46.8%).After 10 years follow up under autovaccine, the number of positive urine cultures decreased from 100% to 87% (P >0.05) and no patient take any curative antibiotics. Conclusion Probelte Pharma autovaccine ® provides a reduction in symptomatic repeated UTI and descrease the use of antibiotics with a good tolerance.
Keywords
Chronic Urinary Tract Infections, Vaccine, Sublingual, Treatment
To cite this article
Gallego-Vilar Daniel, Sanchis-Verdu Laura, Beltran Persiva Jose, Cuñat-Albert Enrique, Cervello-Grima Enrique, Gallego-Gomez Juan, Perez-Mestre Mateo, Autovaccines for Chronic Urinary Tract Infections; Ten Years Follow-Up Experience, American Journal of Life Sciences. Special Issue:Microbiology Research. Vol. 2, No. 6-3, 2014, pp. 13-17. doi: 10.11648/j.ajls.s.2014020603.13
References
[1]
Dielubanza EJ, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am. 2011 Jan;95(1):27-41.
[2]
Williams DH, Schaeffer AJ. Current concepts in urinary tract infections. Minerva Urol Nefrol. 2004 Mar;56(1):15-31.
[3]
Brookman et al. Association between residual urinary volumen and urinary tract infection: prospective trial in 225 male patients. Urologe A. 2010 Sep; 49(9): 1163-8
[4]
Schaeffer AJ, Stuppy BA. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol. 1999 Jan;161(1):207-11
[5]
Hopkins WJ and Uehling DT: Vaccine development for the prevention of urinary tract infections. Curr Infect Dis Rep 2002; 4: 509.
[6]
Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, Jinenez Cruz F, Selvaggi FP; Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol. 2001 Nov;40(5):576-88.
[7]
Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, Fernandez Rivas M, Ribel M, Durham SR: Efficacy and safety of sublingual immunotherapy with grass al- lergen tablets for seasonal allergic rhinocon- junctivitis. J Allergy Clin Immunol 2006; 118:434–440.
[8]
Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, Andre C, de Beaumont O, Melac M: Optimal dose, efficacy, and safety of once-daily sublingual immuno- therapy with a 5-grass pollen tablet for sea- sonal allergic rhinitis. J Allergy Clin Immu- nol 2007;120:1338–1345.
[9]
Gallego Vilar D, Povo Martin I, Gimeno Argente V, Bosquet Sanz M, Garcia Torreles M, Martinez Ramos D, Gallego Gomez J, et al. Autovaccines for urinary tract infections. Urod Aplic. 2008. Vol21;2:99-104.
[10]
Wagenlehner FM, Schmiemann G, Hoyme U, Fünfstück R, Hummers-Pradier E, Kaase M, Knieh E, Selbach I, Sester U, Vahlensieck W, Watermann D, Naber KG. S3-guideline for uncomplicated urinary tract infections - treatment guidelines compliance. Med Monatsschr Pharm. 2011 May;34(5):164-8.
[11]
Hooton TM. Recurrent urinary tract infection in women. Int J Antimi- crob Agents 2001;17:259–68.
[12]
Kahlmeter GJ. An international survey of the antimicrobial suscep- tibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003;51:69– 76.
[13]
Karlowsky JA, Jones ME, Thonsberrry C, Friedland IR, Sahm DF. Trends in antimicrobial susceptibilities among Enterobacteriaceae iso- lated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003;47:1672–80.
[14]
Westenfelder M. Lipoid A, a factor in the pathogenesis of chronic pyelonephritis. Experimental and clinical studies of a lipoid A dependent pathological immune reaction and they have been used, rather empirically, to prevent recurrent infections in the non-immunocompromised host. Fortschr Med. 1979 Feb 8;97(6):245-8.
[15]
Ha US, Cho YH. Immunostimulation with Escherichia coli extract: prevention of recurrent urinary tract infections. Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S63-7.
[16]
Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002 Jun;19(6):451-6.
[17]
Thomas M. Hooton. Recurrent urinay tract infections in women. International journal of Antimicrobial agents. 17 2001; 259-268
[18]
Caron F. [Diagnosis and treatment of community-acquired urinary tract infections in adults: what has changed. Comments on the 2008 guidelines of the French Health Products Safety Agency (AFSSAPS)]. Presse Med. 2010 Jan;39(1):42-8.
[19]
Uehling DT, Hopkins WJ, Balish E, Xing YN and Heisey DM: Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. J Urol 1997; 157: 2049.
[20]
Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007 Apr;177(4):1349-53.
[21]
Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis. 2001 Mar 1;183 Suppl 1:S81-3.
[22]
Fanta C, Bohle B, Hirt W, Siemann U, Horak F, Kraft D, Ebner H, Ebner C. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol. 1999 Nov;120(3):218-24.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186